8LY.F ONCOZENGE AB

Healthcare Biotechnology Frankfurt Exchange
0.2840 EUR
Close of Nov 11, 2026
0.2300 0.7540
Market cap
EUR 7.11M
P/E
-
P/B
8.00x
ROE
-261.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 8LY.F undervalued?

Graham number

The Graham number of ONCOZENGE AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ONCOZENGE AB fundamental analysis

No fundamental analysis for ONCOZENGE AB yet.

ONCOZENGE AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ONCOZENGE AB

OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.

Full company profile